Training can be a bore; dull, predictable sessions shoe-horned into the diary when a meeting room is available or via a virtual session full of muted moments and cross-talk confusion.
The world is re-balancing but the pharmaceutical industry’s engagement with HCPs has been tilted on its axis sending time-honoured engagement tactics into disarray.
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS